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Marrow adipose tissue (MAT) is functionally distinct from both white and brown adipose tissue and can contribute
to systemic and skeletal metabolism. MAT formation is a spatially and temporally defined developmental event,
suggesting that MAT is an organ that serves important functions and, like other organs, can undergo pathologic
change. The well-documented inverse relationship between MAT and bone mineral density has been interpreted to
mean thatMATremoval is apossible therapeutic target forosteoporosis.However, theboneandmetabolicphenotypes
of patients with lipodystrophy argues that retention of MAT may actually be beneficial in some circumstances.
Furthermore, MAT may exist in two forms, regulated and constitutive, with divergent responses to hematopoietic
and nutritional demands. In this review, we discuss the role of MAT in lipodystrophy, bone loss, and metabolism,
and highlight our current understanding of this unique adipose tissue depot.
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Introduction
Advances in the study of marrow adipose tissue
(MAT) have occurred in distinct waves over the past
150 years. In the second half of the 19th century, it
was determined that the skeleton is filled with areas
containing yellowor redmarrow that are distributed
in a defined pattern.1,2 Perhaps owing to the pub-
lication of these results in French and German and
the difficulty of dissemination of research findings
at the time, the idea of there being a distinct pattern
of marrow was largely ignored and forgotten until
Piney’s article “The Anatomy of the Bone Marrow”
in 1922.2 This may have sparked some interest in
the topic, and in the 1930s the histological nature
and distribution of bone marrow fat was defined,
in addition to its possible temperature-dependent
regulation in rats.3–5 Interest waned in the 1940s,
though it was proposed that the bone marrow be
recognized as a site of conventional fat storage.6
In the 1950s and 1960s, MAT became fully recog-
nized as fat with the potential for adipose tissue-
like character, and the term yellow marrow began
to fall out of use in favor of the terms marrow fat
or fatty marrow (Fig. 1).7 The research on marrow
fat began to accelerate at this time, ushering in a
golden age of MAT research in the 1970s that be-
gan with a paper published in Science by Mehdi
Tavassoli in which intrinsic differences between red
and yellow marrow histogenesis were identified.8
He went so far as to suggest that red and yellow
marrow have programmed epigenetic differences,
a concept that is of significant interest today, 43
years later.8 In 1976, Tavassoli, through elegant ul-
trastructural studies on developing tissue, revealed
that theMATadipocyte develops fromauniquepro-
genitor when compared to the white adipose tissue
(WAT) adipocyte.9 This, again, is a line of investi-
gation that is currently of great interest and under
active investigation by Mark Horowitz at Yale Uni-
versity, among others. Finally, Tavassoli showed that
there are two unique populations of MAT within
the bonemarrow and that these cells respond differ-
ently to hematopoietic demands.10 We have recently
observed this phenomenon in a different model,
referring to MAT as either regulated or constitutive,
doi: 10.1111/nyas.12327
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Figure 1. Publications containing the search terms “yellow
marrow,” “marrow fat/fatty marrow,” or “marrow adipose tis-
sue” with time. This graph was generated based on a PubMed
search for the terms of interest. Given poor indexing of ab-
stracts before 1950, several additional references were added in
manually. In addition to general publication trends, this demon-
strates a shift in nomenclature from “yellow marrow” to “mar-
row fat/fattymarrow” in the 1950s and 1960s. Though there was
a resurgence in the use of the term“yellowmarrow” in the 1980s,
its use is declining again in favor of “marrow adipose tissue.”
and are actively working to define its molecular
basis. The cells interspersed with redmarrow, which
we refer to as regulated MAT (rMAT), are depleted
in response to phenylhydrazine-induced hemolysis,
while those in other regions, referred to as constitu-
tive MAT (cMAT), are preserved.10
In the late 1970s and 1980s the term MAT began
to appear in selected manuscripts in recognition
that the marrow fat exists as a distinct adipose tis-
sue organ (Fig. 1). After a period of discovery which
focused on elucidating the basic nature of MAT, in
the 1980s the bone biology community became very
concerned about the potential relationship between
MAT accumulation and bone loss. This led to many
clinical andanimal studies on the topic, castingMAT
as a “villain” in diseases such as osteoporosis.11,12
Today, research on the relationship between MAT
and skeletal metabolism occurs in many groups
on a worldwide scale and publications containing
the terms marrow fat andMAT have increased each
decade since the 1970s (Fig. 1). In addition to under-
standing the impact ofMATonbone, several groups
have recently picked up where Tavassoli left off and
are working diligently to define theMAT progenitor
and to understand the fundamental genetic, epige-
netic, and metabolic differences between MAT and
WAT. This review will explore what we know about
the relationships between MAT, bone, and the body
and provide several hypotheses regarding the role of
MAT in regulation of both skeletal and endocrine
metabolism.
Does the skeleton need fat to be
metabolically healthy?
Under the light microscope, MAT looks histolog-
ically identical to endocrine and mechanical WAT
(Fig. 2). Mechanical WAT is the adipose tissue that
functions as physical padding, for example, on the
palms and soles of hands and feet. Despite simi-
larities to endocrine WAT, we know that mechan-
ical WAT is relatively metabolically inert, while
endocrine WAT plays a major role in satiety, fertil-
ity, and glucose homeostasis.13 Like the differences
between WAT types, MAT is also distinct in both
its gene expression and ability to respond to nutri-
tional status.14 The most puzzling example in re-
cent years is that in states of calorie restriction and
anorexia, the amount of MAT increases while pe-
ripheral WAT is lost.15,16 In addition to WAT, MAT
hasbeen likened toa third typeof adipose, thebrown
adipose tissue (BAT).17 BAT is functionally and his-
tologically distinct from WAT and converts energy
from glucose and triglycerides into heat, an inte-
gral aspect of adaptive thermogenesis (Fig. 2).18 Like
MAT, bothWAT andBAThave the ability to regulate
skeletal metabolism.19–21
Largely owing to the use of marrow as an energy
substrate, it has longbeen recognized that bonemar-
row composition varies by site, with the more red
marrowbeing confined toward themiddle of the an-
imal and the yellow, or fatty, marrow existing on the
periphery (Fig. 3A).2 The earliest fatty change of the
human marrow in the phalanges of the toe begins
at or slightly before birth, regardless of prematurity,
and rapidly accelerates between 4 and 8weeks of age
(Fig. 3B).22 The marrow in the phalanges gradually
matures and reaches full fatty conversion after 1 year
(Fig. 3B).22 MAT continues to accumulate in the ap-
pendicular skeleton fromdistal to proximal until age
20–25, with gradual MAT conversion continuing in
the axial skeleton throughout life (Fig. 3C).2,23 A
similar, highly regulated pattern of development is
recapitulated in many vertebrate species including
mice, rats, and rabbits.24,25 In rabbits, for exam-
ple, the mature pattern of MAT conversion occurs
by age 4–6 months. At birth, sites of high MAT
like the rabbit tibia have a relatively low density of
hematopoietic elements when compared to sites of
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Figure 2. Histology of MAT,WAT, and BAT. (A) Humanmarrow adipose tissue, B: bone. (B) Human subcutaneous white adipose
tissue from the thigh. (C) Mouse brown adipose tissue. H&E stain, 200× magnification.
low MAT such as the lumbar vertebrae.25 As MAT
develops, its density is inversely proportional to this
initial cellularity, suggesting that the distribution of
MAT is programmed from birth.25
Genetic insights into the MAT–skeletal
relationship
Lipodystrophy in humans
Lipodystrophy is a complete or partial loss of body
fat. Surprisingly, loss of body fat can result in insulin
resistance and diabetes. This is generally accompa-
nied by pathologic accumulation of lipid in the liver
and other sites, suggesting that a normal amount
of endocrine adipose tissue is necessary for proper
glucose homeostasis.26 Patients with lipodystrophy
have low circulating levels of the adipokines lep-
tin and adiponectin.26 Lipodystrophy is classified as
generalized or partial depending on the extent of
body-fat loss, and has been linked to genetic muta-
tions in genes includingAGPAT2,BSCL2,CAV1, and
PTRF (Table 1, Fig. 2).26 Depending on the genetic
variant, lipodystrophy occurs as either a failure of
adipocyte formation from birth or normal forma-
tion of adipocytes with a failure of adipocyte main-
tenance and gradual loss of WAT mass over time.
The specific genetic mutations have different ef-
fects on endocrineWAT,mechanicalWAT, andMAT
(Table 1, Fig. 4). The bone phenotype also varies
between subtypes. Comparisons between lipodys-
trophic phenotypes can provide insight into (1) the
impact of MAT on the skeleton and (2) the genetic
and functional differences that exist between WAT
and MAT.
In patients with AGPAT2-associated type 1 con-
genital generalized lipodystrophy (CGL1), both en-
docrine WAT and MAT are lost while mechanical
WAT ismaintained (Table 1, Fig. 4).28,29 In contrast,
BSCL2-linked lipodystrophy (CGL2) results in loss
of all forms of adipose tissue.28 AGPAT2 encodes
for 1-acylglycerol-3-phosphate-O-acyltransferase 2,
which catalyzes the formation of phosphatidic acid,
critical for triacylglycerol synthesis in adipose tissue,
suggesting that both MAT and endocrine WAT rely
on this enzyme for synthesis and subsequent stor-
age of triacylglycerol. The BSCL2 gene encodes for
seipin, a regulator of adipocyte differentiation and
lipid droplet formation.30 Loss of all fat with BSCL2
mutation implies that seipin functions upstream of
adipocyte formation and/or lipid storage in all three
fat types. CGL3 andCGL4 are associatedwithmuta-
tions inCAV1 and PTRF, respectively.31,32 CAV1 en-
codes caveolin 1, a key structural component of 50-
to 100-nm invaginations of the plasma membrane
called caveolae.33 Caveolae account for 20–40% of
the surface of the adipocyte and are major regu-
lators of insulin signaling and lipid trafficking.26
PTRF encodes for cavin, a protein required for sta-
bilization of caveolins and formation of caveolae.31
Unlike CGL1 and CGL2, MAT is retained in both
CGL3 and CGL4, suggesting that MAT can form
and store lipids in the absence of caveolae.31,32
CGL was initially reported in 1954 by Berar-
dinelli, with additional reports in greater detail
by Seip in 1959 leading to its designation as
Berardinelli–Seip Syndrome, a name now synony-
mous with CGL1 or CGL2.34–36 Mutations in the
AGPAT2 or BSCL2 genes account for 95% of
cases of CGL.37 Longitudinal studies in which pa-
tients with CGL were followed for up to 38 years,
in addition to standard case reports, have allowed
for a fairly precise characterization of the bone
phenotype.34,38–40 Ninety-three patients with CGL
in which some form of skeletal analysis was per-
formed are detailed in Table S1 and summarized in
Table 1.28,31,32,34–36,38–56
Our understanding of the skeletal differences be-
tween CGL subtypes is somewhat limited since the
CGL-causing genetic mutation is unknown in the
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Figure 3. Distribution of marrow adipose tissue and changes skeletal adiposity with time. (A) Distribution of marrow adipose
tissue (yellowmarrow) and hematopoietic or redmarrow in an adult skeleton.23 (B) The percentage of subjects with fatty conversion
of the marrow in the phalanges of the 2nd toe at autopsy relative to birth (age 0 weeks). Grade III: somemature adipocytes present,
Grade IV: mostly fat with some islands of hematopoiesis, Grade V: complete fatty conversion.22 (C) Loss of red marrow in the
appendicular (femur) and axial skeleton (rib, sternum, and vertebra) with age. Dashed line: approximate age of mature MAT
phenotype in the appendicular skeleton.23
majority of early reports. However, in 2004, Fu
et al. identified the genetic mutation in 26 fam-
ilies with CGL and concluded that the phenotypic
characteristics of patients withAGPAT2 (CGL1) and
BSCL2 (CGL2) mutations are similar, with the ex-
ception that mental retardation is more prevalent
with BSCL2 mutation (Table 1).55 Since 95% of
patients with CGL have been found to harbor mu-
tations in either AGPAT2 or BSCL2, if we group all
CGL cases of unknown genetic origin with those
identified as CGL1 and CGL2, identifiable patterns
in skeletal development begin to emerge (Table 1).37
In the first decade of life, patients with CGL1 or
CGL2 present with prominent muscularity, acceler-
ated bone growth, advanced skeletal age (>3 years
above their chronological age), cortical thicken-
ing, and skeletal sclerosis.38,41,48,53,55,56 Childrenwith
CGL1 or CGL2 are initially tall, and up to 90% of
their growth occurs in the first 10 years of life.44 Af-
ter this period, growth slows, and adults with CGL
are of average stature.44,57 As the children age, there
is often an increase in radiodensity in the appendic-
ular skeleton, accompanied bymetaphyseal sclerosis
with similar, though less prevalent, changes noted in
the axial skeleton.42,53 The mechanism is unknown,
but this may represent a shift in osteoblast activ-
ity or number in response to the absence of MAT
thatwould normally be forming in the appendicular
skeleton at this age (Fig. 3C). It could also be a re-
sponse to themuscular hypertrophy associated with
CGL or potentiation of osteoblast activity by excess
circulating insulin.58,59 The skeletal development of
patients with CGL3 (CAV1) or CGL4 (PTRF) raises
doubts about the latter possibilities.31,32,50,51 Like
those with CGL1 and CGL2, patients with CGL4
tend to have accelerated skeletal growth during the
first year of life, however, this rapidly slows and
skeletal age is normal or decreased in childhood. In
addition, sclerosis is not a common feature of CGL3
or CGL4, rather, bone density tends to decrease, in
some cases leading to development of osteopenia or
osteoporosis. This may be linked to the persistence
of MAT in patients with CGL3 and CGL4 that is not
normally present in CGL1 or CGL2 (Table 1, Fig. 4).
In adolescence, a subset of patients with CGL1
or CGL2 develop osteolytic cyst-like lesions in the
long bones and occasionally the phalanges that are
progressive and can result in pathologic fractures
(Fig. 5).38,41,43,47,49,55 Biopsy results have been re-
ported in several cases and generally contain bone
fragments, normal hematopoietic marrow, and a
proliferation of vascular structures that has been
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Table 1. The adipose tissue phenotype, skeletal changes, and clinical findings associated with CGL1, CGL2, CGL3,
and CGL4
Adipose tissue phenotype CGL1: AGPAT2 CGL2: BSCL2 CGL3: CAV1 CGL4: PTRF
Visceral WAT Absent Absent Absent Absent
Subcutaneous WAT Absent Absent Absent Absent
Mechanical WAT Present Absent Partial loss Partial loss
MAT Absent Absent Present Present
Skeletal phenotype CGL1/2/Unknown (75 Total) CGL3/4 (18 Total)
Age 0–1
Rapid growth/advanced skeletal age 2/2 (73 ND) ND 10/10 (8 ND)
Sclerosis 3/4 (71 ND) ND
Bone density Increased 4/4 (71 ND) ND
Age 1–10
Advanced skeletal age 23/25 (50 ND) ND 0/12 (6 ND)
Sclerosis 10/15 (60 ND) ND 0/10 (8 ND)
Bone density Increased 7/7 (68 ND) ND
Bone cysts 0/13 (62 ND) ND
Age 10–20+
Advanced skeletal age 1/3 (72 ND) ND 1/3 (15 ND)
Sclerosis 9/10 (65 ND) 0/1 ND
Bone density Increased 10/10 (65 ND) Low Low 2/2 (16 ND)
Bone cysts 22/32 (43 ND) 0/1 0/1 (17 ND)
Clinical findings CGL1/2/Unknown (75 Total) CGL3/4 (18 Total)
Acanthosis nigricans 55/62 (13 ND) 1/1 0/18
Prominent musculature 52/52 (23 ND) 1/1 17/18
Diabetes 33/48 (27 ND) 1/1 0/18
Age of diabetes onset 12.1 ± 1.2 Years Old (N = 12) Age 13 N/A
High serum triglycerides 46/57 (18 ND) 1/1 4/16 (2 ND)
High serum insulin 16/19 (56 ND) 1/1 4/16 (2 ND)
Mental retardation 0/10 (4 ND) 3/5 (7 ND) 0/1 0/7 (10 ND)
Note: This table summarizes the findings from Table S1, which lists data from 93 patients with congenital generalized
lipodystrophy (CGL) in which some form of skeletal analysis was performed. Data was not reported for all param-
eters on each patient and they are indicated as ND, no data. CGL. congenital generalized lipodystrophy, AGPAT2.
1-acylglycerol-3-phosphate-O-acyltransferase 2. BSCL2. Berardinelli-Seip congenital lipodystrophy 2. CAV1, caveolin
1. PTRF, polymerase I and transcript release factor. WAT, white adipose tissue. MAT, marrow adipose tissue.
likened to cystic angiomatosis.41,49 In one case, an
epithelial cyst lining was also noted.47 The fac-
tors leading to cyst formation have sometimes
been attributed to environment, as in three cases
not all CGL-affected members of the same fam-
ily demonstrated evidence of cystic bone changes
(Table S1).38,47,55 However, in two of the three re-
ports, the family members without osseous cysts
were age 11 or younger.47,55 Thus, the unaffected
family members may have simply been too young
for the cystic phenotype to be present (Table 1).
Given the lack of marrow fat in these patients, the
expected development of MAT and conversion of
red to yellowmarrow during childhood and adoles-
cence fails to occur (Fig. 3). Thus, cyst formation at
this time may represent a local reaction to the fail-
ure ofMAT conversion. This is further supported by
skeletal findings in acquired generalized lipodystro-
phy (AGL), CGL3, and CGL4. In AGL, the adipose
tissue forms normally but WAT is subsequently lost
during childhood and adolescence.60 In contrast to
AGPAT2- and BSCL2-linked CGL, MAT in patients
with AGL, CGL3, and CGL4 is generally preserved
(Fig. 4).60 Perhaps due to the preservationofMAT in
AGL, cystic bone lesions of any type are exceedingly
rare and have only been noted in four of 64 cases
in the literature (Fig. 5).58,61 Similarly, they have
not been documented in any patients with CGL3 or
CGL4. This is in contrast to the presence of cysts
in 22 of 32 patients with CGL1, CGL2, or CGL of
18 Ann. N.Y. Acad. Sci. 1311 (2014) 14–30 C© 2014 New York Academy of Sciences.
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Figure 4. T1-weighted MRI images of WAT and MAT in CGL. Transverse T1-weighted MRI cross-sections of the limb (top row)
and skull at the level of the orbits (bottom row) in patients with CGL as compared to control. In the limb of a normal control a
thick layer of subcutaneous adipose tissue (white) is present around a core of muscle (gray). In the center is bone (black) that is
filled with marrow adipose tissue (white). Both subcutaneous and marrow adipose tissue are absent in CGL1 and CGL2. In CGL3
and CGL4, subcutaneous fat is lost while marrow fat is maintained. In the cranial section, a layer of mechanical white adipose tissue
is present around the skull and behind the orbits. Both mechanical depots are maintained in CGL1, both are lost in CGL2, and
the fat behind the orbits but not around the skull is present in CGL3 and CGL4. Images for normal (age 30, female, femur), CGL1
(age 31, female, femur), and CGL2 (age 11, female, femur) from Ref. 28; CGL3 (age 19, female, tibia) from Ref. 32; and CGL4 (Age
14, male, humerus) from Ref. 50.
unknown type that were monitored to or past ado-
lescence and checked for cyst formation (Table 1,
Table S1). These findings support the notion that
MAT plays an important role in the maintenance of
skeletal homeostasis.
There are several important observations that can
be derived from the human condition. First, neither
MAT nor WAT is necessary for basic skeletal pat-
terning and formation. However, loss of WAT in
CGL is sufficient to induce skeletal changes ranging
fromosteosclerosis, advanced bone age, and cortical
thickening (in the absence of MAT) to osteopenia
and osteoporosis (when MAT is maintained). Sec-
ond, retention of MAT may protect the skeleton
from cyst formation during adolescence and patho-
logic fractures later in life. These findings suggest
a bell-shaped curve in which both too little MAT
or too much MAT are not ideal. In addition to ef-
fects on the skeleton, the lipodystrophies raise the
possibility that MAT may be able to functionally
contribute to systemic metabolism—especially in
times when WAT is decreased or absent. It is clear
that the presence of MAT is not sufficient to com-
pletely compensate for the loss of endocrine WAT,
however, the prevalence of hyperinsulinemia, high
serum triglycerides, acanthosis nigricans (a sign of
insulin resistance), and diabetes is lower in pa-
tients with CGL4when compared to CGL1 or CGL2
(Table 1). This could imply that preservation of
MAT in CGL decreases the severity of diabetes and
insulin resistance. The rarity of reports limits any
definitive conclusions but suggests that further in-
vestigation of this relationship may prove fruitful.
For example, preservation of MAT may improve
insulin sensitivity through secretion of adipokines,
including adiponectin, into the systemic circulation.
In mice, adiponectin decreases insulin resistance by
limiting lipid storage in muscle and the liver; fur-
thermore, restoration of circulating adiponectin can
help to reverse the insulin resistance associated with
lipodystrophy.27,62
Genetically engineered mouse models
CGL is exceedingly rare, estimated to affect only
one in every 5–10 million people in the United
States.60 Thus, mouse models with similar genetic
mutations have been generated to provide pheno-
typic andmechanistic insights. Mice with CGL tend
to have phenotypes that are significantly less se-
vere than humans. CGL1 AGPAT2−/− mice most
closely mimic the human condition with nearly ab-
sent adipose tissue, diabetes, high circulating insulin
and triglycerides, and low circulating leptin.63 Un-
fortunately, information regarding the bone phe-
notype of these animals has not been published.
Three different BSCL2 knock-out mice have been
made, all of which show a 50–70% reduction in
WAT and BAT, diabetes, high circulating insulin,
19Ann. N.Y. Acad. Sci. 1311 (2014) 14–30 C© 2014 New York Academy of Sciences.
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Figure 5. Osteolytic skeletal lesions in CGL and AGL. (A), (B) Multicystic transformation of the distal femur in a 42-year-old
Kurdish woman with CGL.54 The lesion remained relatively unchanged between age 31 and 42 and showed coarse trabeculation of
cystic areas filled with high, fluid-like signal intensity on T2-weightedMRI images.54 (C) Bilateral lesions of the distal humeri, distal
radii, proximal and distal ulnae, and phalanges of the hand were noted in a 17-year-old female with CGL that became progressively
worse by age 22 and resulted in pathologic fracture of the right humerus at age 23 and the left forearm at age 24.47 Lesions of the
left distal humerus (white arrows) and proximal ulna (black arrows) are shown in panel C. (D) Bilateral unicameral bone cysts of
the femoral diaphysis (right femur pictured) in a 13-year-old male with acquired general lipodystrophy.61 Distal extension noted
by the white arrows.
and low circulating leptin.64–66 However, the nor-
mal baseline increase in circulating triglycerides is
not present and again, bone phenotyping has not
yet been published.64–66 CAV1 (CGL3) and PTRF
(CGL4) knock-out mice have also been generated
and reveal an even wider divergence from the strik-
ing humanphenotype. Instead of near complete loss
of body fat, WAT is reduced by only up to 40%.
Specifically, CAV1−/− mice appear quite similar ini-
tially and reveal their adipose tissue phenotype only
with age or dietary manipulation. This phenotype
consists of small adipocytes and a robust resistance
to high-fat diet–induced obesity.67 Unlike the hu-
man report of a CAV1 mutation, these mice do not
have diabetes or high circulating insulin, though
high serumtriglycerides and low levels of adipokines
persist.67 The bone volume of CAV1−/− mice is sig-
nificantly increased at 5–8 weeks of age due to an
underlying increase in the bone formation rate.68
The bone phenotype of PTRF knock-out mice is
currently unknown.69
Adipokines
Adipocyte-secreted cytokines (adipokines) such as
leptin can regulate bone formation through central
induction of the sympathetic nervous system.70,71
Clinical studies including the 24 reports detailed
in Table S2 have revealed, if anything, a mild,
gender-specific correlation between serum lep-
tin level and bone mineral density in humans
(Table S2). While leptin often correlates positively
with BMD in females,72–90 the opposite is noted
in males.72,74,75,81,82,85,86,88,91–94 In the genetic mod-
els of lipodystrophy, both leptin and adiponectin
circulate at low levels despite highly divergent bone
phenotypes.27 Simultaneous restorationof both lep-
tin and adiponectin, or in some cases leptin alone, is
sufficient to normalize insulin sensitivity in lipodys-
trophic mice.62,95 Similarly, in humans, recombi-
nant leptin has been used in patients with difficult-
to-treat lipodystrophy, resulting in improvements
in insulin sensitivity, glucose tolerance, and body
composition.96 Despite significant improvements in
metabolic parameters and restorationof physiologic
leptin levels in humans, recombinant leptin did not
change bone mineral density after 4–18 months of
replacement therapy.96–98 This may be due to the
small sample size of the study, inclusion of different
forms of lipodystrophies, or the length of follow-
up, and does not rule out the possibility that leptin,
20 Ann. N.Y. Acad. Sci. 1311 (2014) 14–30 C© 2014 New York Academy of Sciences.
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or other adipokines, can regulate bone formation—
especially when present in excess. However, since
regulation of bone by adipokines has been covered
extensively in previous reviews, we will not include
any further discussion here.99
MAT and bone loss
Human and animal models
Since the 1980s, it has been a recurring paradigm
that MAT is a negative regulator of bone formation.
Human studies have correlated increases in MAT
accumulation with decreases in cortical bone,100
low bone mineral density,101 decreases in bone
volume,102 decreased bone formation rate,102 os-
teoporosis, andosteopenia.103 Despite these correla-
tions, it is unclear whether increases inMATdirectly
regulate bone formation and strength or simply rep-
resent a passive response to bone loss or changes in
the marrow microenvironment. For example, MAT
is increased in premenopausal women with idio-
pathic osteoporosis.102 However, the expected neg-
ative correlations between MAT volume and bone
formation, while present in the control population,
were not present in those with idiopathic osteo-
porosis despite loss of bone density and increased
rate of fracture.102 This implies that MAT accumu-
lation is not necessary for loss of bone integrity, at
least in some situations. This is further supported
in rodent models.104 For example, mice deficient in
11-hydroxysteroid dehydrogenase type I fail to de-
velopmarrow fat in the proximal tibia, yet maintain
the same skeletal architecture and rate of bone loss
with age when compared to wild-typemice.104 Sim-
ilarly, Tornvig et al. inducedMAT formation inmice
with troglitazone and concluded that in the absence
of a challenge where production of blood or bone is
necessary, the accumulation of adipose in the bone
marrow does not change the trabecular volume.105
It is established that the adult C57BL/6J mouse
tibia, one of the fattiest long bones of any skele-
ton, contains <5% MAT by volume based on
osmium staining and CT analyses (unpublished ob-
servation). This is consistent with the study refer-
enced above, which observed an increase in MAT at
the proximal tibia from0.2± 0.3% to 4.7± 2.1% af-
ter treatment with troglitazone.105 In the C3H/HeJ
mouse strain, baseline levels of MAT increase to
20% of marrow volume (unpublished quantifica-
tion). This is in dramatic contrast to an adult human
tibia which is filled with 70–100%MAT.23 There are
exceptions, but it seems that the larger the model,
the fattier the marrow. Rats are closer to the human
condition and, on the basis of a review of bone his-
tology, oldermales tend to contain closer to 30–50%
MAT by volume (unpublished observation). Rabbit
tibias, one of the most popular models historically
for MAT research, reach levels of 70% or more. The
proximal femur, normally about 40–50% MAT by
volume in humans, is also essentially the same in
rabbits.106 Variations between species make model
selection critical forMAT research, since any impact
of MAT on skeletal or systemic metabolism in mice
is likely to be amplified in larger animals, including
humans.
In order to quantify the relationship between
MAT formation and bone loss, long-term tempo-
ral studies have been performed. Even with this
approach, interpretation is challenging in the ab-
sence of a negative control model that resists MAT
accumulation. For example, in a temporal study
by Li et al., osteoporosis was induced in 5-month-
old New Zealand White rabbits with 1.5 mg/kg/day
methylprednisolone sodium succinate for 4 weeks,
followed by 0.35 mg/kg three times per week for
an additional 8 weeks.106 MRI and DXA scans of
treatment and control groups were completed at 4,
8, and 12 weeks.106 Marrow lipids were significantly
increased in the proximal femur by week 4 (+35%)
at which time bone mineral density (BMD) was de-
creased onDXAby 4.5%, though this was not statis-
tically significant. The pattern continued to progress
at week 8 with a significant 60.5% increase in mar-
row lipids and a 13.3% decrease in BMD when
compared to baseline readings. However, at week
12, despite an additional 11.8% increase in marrow
lipids on MRI and a 26% increase in adipocyte vol-
umebyhistology, BMDremainedunchanged. Thus,
both BMD and MAT are regulated by glucocorti-
coid treatment. In addition, changes in MAT occur
more rapidly and to a greater extent.However, in the
absence of a control population in which MAT for-
mation was blocked, this fails to prove that MAT
accumulation directly regulates BMD. A similar
study that analyzed temporal changes in MAT and
bone volume in rats with OVX-induced osteoporo-
sis further argues this point. At 4 weeks after OVX
induction, the authors observed a 47.4% decrease
in trabecular bone volume at the tibial metaphysis
with no change in the volume of adipocytes.107 By
12 weeks post-OVX there was, however, a 173%
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increase in MAT volume in addition to a 40.6% loss
of bone volume relative to control animals.107 Again,
these results suggest that both MAT and bone vol-
ume are regulated in response to OVX. However,
in this case bone loss occurred before changes in
MAT.107 It may be that MAT precedes bone loss
in some forms of osteoporosis (i.e., glucocorticoid-
induced) but not others. If this becomes well de-
fined with temporal studies in humans, even in the
absence of a causal relationship between MAT and
bone loss, MAT accumulation may be able to serve
as a biomarker to alert the provider that the patient
is at high risk for future loss of BMD.
Histological studies in rats and dogs have demon-
strated decreased osteoblast activity, osteoclast
numbers, and bone formation rate at sites of high
marrow fat when compared to sites of low mar-
row fat.11,108 Sites with high levels of MAT also
have a diminished response to osteoanabolic agents
including basic fibroblast growth factor and inter-
mittent parathyroid hormone in rodents.109,110 It
may be that MAT decreases osteoblast and osteo-
clast activity, effectively slowing bone turnover and
thus decreasing the rate of bone accumulation or
loss.11,108 For example, the presence of MAT actu-
ally protects against cancellous bone loss in rats with
OVX-induced osteoporosis.108,111 In addition to de-
creasing the rate of bone turnover, it is possible that
marrow fat crowds out T cells that have been shown
to participate in OVX-induced bone loss.112 Fatty
marrow can also aromatize circulating androgens
to estrogen, which may decrease the effects of OVX
at sites of high MAT.113,114
In summary, it seems indisputable that bothMAT
accumulation and bone loss occur with age and are
temporally linked in many conditions. While it is
possible that in some cases the marrow adipocytes
or their formation contributes to loss of skeletal in-
tegrity, there is more likely a context-specific nature
to the appearance of marrow fat that may influence
bone remodeling in several ways.
Two types of marrow fat
In addition to its divergence from WAT, MAT may
exist in two forms. Tavassoli, in 1976, demonstrated
the presence of two different types of adipocytes
in rabbit marrow—those that stain with performic
acid Schiff (PFAS) and those that do not.10 The
PFAS reaction relies on oxidation of the ethylenic
linkages in unsaturated fats to aldehyde and pro-
cessing with Schiff reagent to generate a red/purple
color. This suggests that bone marrow adipocytes
interspersed with hematopoietic elements may con-
tain a different class of fatty acids than those with-
out adjacent hematopoiesis. These two populations
respond differently to induction of hematopoiesis
and anemia. As discussed above, the rMAT cells
interspersed with red marrow are depleted in re-
sponse tophenylhydrazine-inducedhemolysiswhile
the cMAT is preserved.10 According on the liter-
ature, rMAT and cMAT may also respond differ-
ently to starvation. Cohen, in 1965, placed rabbits
on a water-only diet for 28 days and observed a
50–75% reduction in total marrow lipid in the ribs,
humerus, femur, tibia, radius, and ulna.115 Though
not directly quantified, it was mentioned that the
distal bones preserved more of their MAT than the
proximal bones. They also mentioned that the mar-
row had a gelatinous appearance, which may be
similar to the serous transformation that occurs in
the marrow of severely anorexic patients.116 Tavas-
soli went on to demonstrate that the cMAT at the
distal tibia is not mobilized in the rabbit even af-
ter 10 days of starvation and loss of 22% of to-
tal body mass, further confirming its resilience.117
The concept that rMAT and cMAT may respond
differently to nutritional status is interesting, es-
pecially given recent publications that show that
MAT increases in states of anorexia and calorie
restriction.15,16
We hypothesize that cMAT is programmed to de-
velop in a very specific temporal and spatial pattern
prior to age 25, while rMAT forms more gradually
throughout life. In rodentmodels, cMAT is found in
the tail, paws, and distal tibia, while rMAT is present
in the proximal tibia and femur. It is also possi-
ble that rMAT forms first and matures into cMAT
with time. If true, this has implications for diseases
including osteoporosis, which has been associated
with a decrease in MAT unsaturation.118 A shift in
marrow fat composition to higher levels of saturated
lipid has also recently been correlated with fragility
fractures in postmenopausal women.119 Thus, per-
haps it is not simply the presence of MAT but rather
a specific type of MAT that negatively affects bone
density and metabolism. For example, the paratra-
becular distribution of marrow fat accumulation
in osteoporosis is dramatically different than the
centralized pattern of marrow fat in plasmacytoma
(Fig. 6).12
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Figure 6. Distribution ofmarrow adipose tissue in osteoporo-
sis and plasmacytoma. (A) 75-year-old female with osteoporosis
and paratrabecular accumulation ofmarrow adipocytes. (B) In-
crease in marrow adipocytes in central spaces in a patient with
plasmacytoma.12
MAT and systemic metabolism
Skeletal health and total MAT are acutely respon-
sive to changes in systemic metabolism (reviewed
elsewhere).120 However, the capacity of MAT to ac-
tively contribute to glucose homeostasis or energy
balance is unclear. As noted in lipodystrophy, pa-
tients with PTRFmutations have a decreased preva-
lence of insulin resistance and diabetes when com-
pared to those with AGPAT2 or BSCL2 mutations
(Table 1). There are many possible explanations,
but one consideration is that MAT is maintained
in the former but lost in the latter. This prompts
the question, Is there enough MAT to actually con-
tribute to systemic metabolism? MRI has been used
to quantify total body fat and compare it to the total
volume ofMAT in hundreds of adult patients (aver-
age age 40–50 years).101,121 The total MAT volume
ranges from 0.51 to 3.28 L (mean 1.5 L). In these
patients, MAT made up 1.1–43.2% (mean7%) of
the total adipose tissue volume.101,121 The men and
women in these studies were of relatively normal
size and had an average BMI of 24–28 kg/m2.101,121
Similar results were obtained in a younger cohort of
280 men and women (average age 30), with the
proportion of MAT ranging from 1.1% to 31.6%
(mean 8.0%) of total adipose mass.122 These pa-
tients had an average BMI of 25–26 kg/m2.122 In
contrast, the BMI of an average anorexic patient
is approximately 17–18 kg/m2 due to loss of body
fat.16 The proportion of MAT is further amplified
in these patients, since MAT, unlike WAT, increases
during calorie restriction and is high in anorexic
patients.15,16 Thus, we estimate that the normal pro-
portion of MAT would be robustly amplified both
in individuals with anorexia and those with MAT-
sparing lipodystrophy, to levels exceeding 30–40%.
Based on these findings, it would appear that MAT
in humans is of a large enough size and proportion
relative to peripheralWAT tomake a significant con-
tribution to metabolism, especially in states of low
body fat.
So, why does MAT increase in calorie restric-
tion and anorexia? The fundamental mechanism
remains under investigation, but several hypothe-
ses regarding the function of MAT have been pro-
posed. For example, MAT may secrete adipokines,
such as adiponectin, that can increase insulin sen-
sitivity and promote appetite to push the body to-
ward metabolic homeostasis during the early stages
of starvation. It has also been proposed that accu-
mulation of MAT may be a survival mechanism. In
this scenario, MAT serves as an energy reserve that
can be leveraged during the final stages of starvation
to provide several additional days of life.123 It is also
possible that MAT accumulates in response to loss
of bone mineral, perhaps regulated by signals from
the osteocyte.
MAT as an energetically favorable alternative
The above hypotheses speak to the integration of
MAT with whole-body metabolism and survival,
but neither provides a rationale for why energy is
stored in the skeleton instead of at an extra-skeletal
site. In order to answer this question we must first
consider the composition and function of the bones.
The skeleton fulfills two major roles in an adult:
structural support and blood cell production. Bone
turnover and hematopoiesis are highly resource in-
tensive and require significant amounts of energy.
Marrow fat, on the other hand, is relatively inert in
its energy requirements. Thus, from the perspective
of the localmicroenvironment, in times of impaired
nutrition, where energy reserves are low, it makes
sense to decrease the energy allocation for bone
turnover and hematopoiesis in favor of MAT for-
mation. This would favor use of dwindling energy
reserves for critical life-sustaining processes. In this
scenario, storing energy in the bones asMAT during
starvationmaymake sense fromboth a systemic and
a local perspective. On the other hand, it could be
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argued that marrow is life sustaining and that MAT
increases the potential energy reserves to maintain
basal hematopoietic and skeletal function. Regard-
less of the underlying mechanism, once nutrition is
restored rMAT in particular can be depleted in favor
of hematopoiesis.10
Temperature-dependent regulation of MAT
The formation and distribution of MAT has also
been linked to changes in temperature. Though this
theory became well established in the 1930s, many
fail to realize that it was repeatedly challenged dur-
ing the latter half of the 19th century. Since stud-
ies pertaining to the relationship between temper-
ature and MAT have been recently revived in the
world of MAT research, we will briefly review the
evidence for this observation.124 In 1936, Huggins
et al. published a study in rats showing that looping
the intact, attached tail with implantation of the dis-
tal tail vertebrae in the peritoneal cavity of an adult
rat results in loss of the mature marrow fat after
several months in the implanted vertebrae, with no
change in those outside the body cavity.5 In a similar
manner, tail vertebrae harvested from rats shortly
after birth and implanted into the peritoneum of
an adult host resisted MAT accumulation in the re-
gions of the epiphysis and metaphysis, but not the
diaphysis.5 It was concluded that physiologic tem-
peratures inhibit MAT formation and cause conver-
sion of mature yellow marrow to hematopoietically
active tissue. Though this temperature hypothesis
of MAT formation rapidly gained favor, follow-up
studies in 1956, 1966, and 1979 showed only a mild
reduction, or no change, in marrow fat of adult rats
after similar experiments.8,24,125,126 In adult humans,
the temperature of the bone marrow is 1.6–4.8 °C
below normal body temperature.127 In six adult pa-
tients where the temperature was measured at both
the iliac crest (red marrow) and tibia (yellow mar-
row), the temperature was higher at the iliac site
by 0.8–1.8 °C in only three of the six patients.127
In the other three patients, the temperature was
lower by 1.1–2 °C. In the tail of mice, the marrow
temperature from proximal to distal decreases by
10 °C.125 However, the marked transition between
hematopoietic and fatty marrow in the first two
caudal vertebrae exists independently of any tem-
perature variation.125 A study in dogs undergoing
whole-body hyperthermia showed that, compared
to core body temperature, the temperature of the
marrow in the ilium, humerus, and tibia was only
0.27 °C, 0.40 °C, and 0.95 °C lower, respectively.128
The above findings prompt the question, Is a<1 °C
variation in temperature across the skeleton ac-
tually relevant to marrow fat accumulation and
maintenance? The results seem to argue against
such a notion in the adult, though the possibil-
ity that temperature plays a role in MAT forma-
tion during the early stages of development remains
intriguing.24
While the role of temperature in early MAT de-
velopment cannot be completely ignored, it must be
considered as a component of a much more com-
plex system. For example, induction of hematopoi-
etic demand can synergize with increases in tem-
perature to prevent de novo development of MAT in
a newborn animal or to reduce MAT in an adult
rat.5,24,129 This reinforces the concept that MAT
formation is reciprocally related to hematopoietic
demand.
Clinical regulation of MAT
Given the clinical correlations between increases
in MAT and decreases in bone, it is not surpris-
ing that targeting MAT apoptosis has been pro-
posed as a treatment for osteoporosis.130 However,
without pharmacologic intervention, it is very dif-
ficult to get rid of marrow fat (especially cMAT).
For example, 24 healthy women 25–40 years of
age underwent bed rest for 60 days.131 During this
60-day period, the fat fraction in the bone marrow
asmeasured byMRI increased by 2.5%. The authors
estimate that this increase is 25 times higher than the
expected change over 60 days in age-matched am-
bulatory controls. The increase in MAT persisted
1 year later regardless of exercise and nutritional
interventions.131 In addition, it is well known that
the level of MAT increases robustly after irradiation
of the skeleton due to local changes in the bone
microenvironment.132 The initial response of bone
marrow to irradiation is congestion and edema. The
rate of esterification of C14-labeled fatty acids be-
comes elevated as early as 24 hours after irradiation
in rats.132 In mice, it takes 10–14 days for maximal
formationof histologically identifiableMATafter ir-
radiation and bone marrow reconstitution (unpub-
lishedobservation). Inhumans, at doses of radiation
higher than 50Gy, it takes at least 6months formor-
phological increases in MAT to become evident on
MRI.133 At doses of less than 50Gy, 1 year ormore is
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Figure 7. Reconversion of yellow to red marrow in hypertensive heart failure. (A) Control femur from a 61-year-old male. (B)
Right femur from a 63-year-old female with hypertensive heart failure. (C) Diagram of marrow content in 10 control female femurs
at autopsy (white = yellow marrow, black = red marrow). (D) Diagram of marrow content of 10 femurs from female patients with
hypertensive heart failure at autopsy.136
needed before injury to the hematopoietic tissue be-
comes apparent.133 The difference in timing is strik-
ing, but the recovery rate in humans is even more
astonishing. Casamassima et al. analyzed vertebral
MAT content by MRI of 35 patients that underwent
radiation therapy.133 In 22 of the 35 patients, persis-
tent depletion of hematopoietic tissue and accumu-
lation of MAT was observed at time points ranging
from 6 months to 15 years after irradiation. Total
recovery of the vertebral marrow to its normal ratio
of hematopoiesis with loss of MAT was only noted
in 11 of 35 patients. This occurred at time points of
7–9 years postirradiation for doses of 1.25 Gy and
10–23 years for doses of >20 Gy.133 These studies
demonstrate the amazing persistence of MAT accu-
mulation in humans. In the setting of irradiation, to
limitMAT accumulation itmaymake sense to target
inhibition of MAT formation rather than induction
of MAT apoptosis. This is supported by work in
rodents. Inhibition of MAT accumulation in trans-
genic mice undergoing radiation and bone marrow
reconstitution increases hematopoietic populations
and bone formation postirradiation compared with
MAT-rich wild-type controls.134 In patients who al-
readyhavehigh levels ofMAT,MATreductionmight
be beneficial to bone formation. Mechanical abla-
tion of the marrow (including the MAT) induces a
robust healing response, including large amounts of
trabecular bone formation. However, this is tran-
sient, and newly formed bone returns to baseline
within three weeks.135 This suggests the need to de-
velop strategies for bone maintenance after MAT or
marrow removal to have a lasting positive impact.
In human patients, reconversion of normal MAT
to hematopoietic marrow generally occurs only in
the background of systemic pathology. Shillingford
et al. reviewed femoral MAT content of 200 pa-
tients at autopsy who presented with comorbidi-
ties such as hypertension, mitral stenosis, emphy-
sema, aortic valve disease, and cardiac failure.136
They observed that men have more MAT than
women (also true in the C3Hmouse strain, unpub-
lished observation) and that red marrow reconver-
sion was specifically associated with hypertension
in the presence of heart failure (Fig. 7). Hyperten-
sion only (without heart failure) was not sufficient
to alter the pattern of red and yellow marrow. Mi-
tral stenosis, aortic valve disease, and emphysema
with cardiac failure increased red marrow conver-
sion to a lesser extent.136 Marathon runners also
have higher percentages of red marrow at the dis-
tal femur (43%) compared with control individuals
(3%) and those with symptomatic knee problems
(15%).137 Thismay be related to sports anemia, with
low red blood cell counts, low hematocrit and/or
low hemoglobin levels in otherwise healthy athletes.
Induction of anemia in dogs by weekly bleeding
resulted in a variable conversion of MAT to red
marrow (from 0% to 100%).138 Anemia-induced
lipemia in rabbits is more consistent and, in one
study, was prevented by transaction of the spinal
cord at the 4th thoracic vertebrae.139 In light of
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this finding, one potential common theme between
anemia, cardiac failure, and calorie restriction is the
regulation of sympathetic tone. Induction of the
sympathetic nervous system may be sufficient
to induce lipolysis and/or apoptosis in marrow
adipocytes. This is supported by studies in which
leptin administered to the brain causes rapid loss of
MAT in rats.140 This is presumed to be due to induc-
tion of sympathetic outflow by leptin, though this
possibility has not been directly tested. Future stud-
ies will be needed to define the ability of the sympa-
thetic nervous system to regulate MAT formation,
lipolysis, and apoptosis. Unfortunately, induction
of sympathetic tone is also known to increase bone
loss;70 thus, the effects on MAT would need to be
separated from the effects on the bone to have a
positive clinical impact.
Finally, we have to consider the possibility that
MAT is an essential component of the bonemarrow
microenvironment and that removal might actu-
ally be detrimental to skeletal and systemic health.
One benefit of MAT is that, though it is difficult
to remove, rMAT in particular has the capacity for
plasticity when hematopoietic demand is increased.
Indeed, rMAT is preferentially depleted in response
tophenylhydrazine-inducedhemolysis,while cMAT
is maintained.10 In addition, if hematopoietic ac-
tivity were retained throughout the entire skele-
ton at the expense of MAT, the energy demand for
hematopoiesis would be incredibly costly. MAT, in
this way, helps to balance skeletal-energy utilization
and blood cell formation.
Finally, we are just beginning to understand
the potential of MAT to secrete insulin-sensitizing
adipokines in states of profound starvation or
lipodystrophy.
Prospects and conclusions
The precise spatial and temporal conservation of
MAT development implies that marrow fat forma-
tion is a defined developmental event. This suggests
that physiologic MAT is an organ that serves an
important function and, like other organs, can un-
dergo pathologic changes. We have discussed how
pathologies such as osteoporosis may be related not
only to the amount of MAT but also perhaps to the
proportion of two different types of MAT (rMAT
and cMAT). We have also determined, through ex-
amining the lipodystrophies, that loss of MAT can
contribute to altered skeletal development, cyst for-
mation, and pathologic fracture. In addition, MAT
may be a central regulator of skeletal energy allo-
cation between bone turnover and hematopoiesis;
andMATmay contribute to systemicmetabolism in
times of starvation through secretion of adipokines
that regulate insulin sensitivity. Thus, it seems that
having just the right amount of MAT is essential
to skeletal health. Newer animal models and clini-
cal and metabolic studies are likely to shed further
light on the origin of marrow adipocytes and their
function.
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